Madrigal Pharmaceuticals, Inc.(MDGL)股价今日盘中大涨5.92%,引起市场高度关注。这一涨势或受到同行业个股的推动。
公司所在的生物技术行业整体上涨0.38%。旗下心脑血管和非酒精性脂肪性肝炎治疗药物MGL-3196前景备受看好。该药物目前处于临床阶段,有望成为公司核心产品。
另外,公司最新财报数据令投资者对其长期发展充满信心。公司去年实现营收6218万美元,虽然净利润暂时为负,但未来潜力可期。投行给予81%买入评级,反映了公司前景获得广泛认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.